Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
10:15am, Tuesday, 05'th Sep 2023
Novartis' biosimilar candidate to Eylea has proven just as safe and effective. The medicine could generate $500 million in annual sales for the Swiss drugmaker.
Novartis sues US government over Medicare drug price regulation
04:20pm, Friday, 01'st Sep 2023
Swiss drugmaker Novartis on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine Entrest
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
07:01am, Friday, 01'st Sep 2023
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
03:02pm, Tuesday, 29'th Aug 2023
Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
10 Drugs Selected for Medicare Price Reduction
12:01pm, Tuesday, 29'th Aug 2023
We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
10:31am, Tuesday, 29'th Aug 2023
Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
12:02pm, Monday, 28'th Aug 2023
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Oncology Market's Huge Potential Puts These Stocks in Focus
09:46am, Monday, 28'th Aug 2023
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meanin
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
11:16am, Monday, 21'st Aug 2023
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are wo
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
02:05pm, Friday, 18'th Aug 2023
Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
10:55am, Tuesday, 15'th Aug 2023
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
3 Unstoppable Dividend Stocks to Buy Right Now
06:15am, Saturday, 12'th Aug 2023
AbbVie is more unstoppable than you might think. Johnson & Johnson faces some challenges but remains a solid pick for long-term investors.
2 Stocks That Raised Their Guidance in July
10:01am, Wednesday, 26'th Jul 2023
Many of Novartis' top drugs saw their revenue generation grow by double digits this year. PepsiCo did not see big drops in sales volume despite increasing its prices.
The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos
07:54pm, Monday, 24'th Jul 2023
Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the worl
Novartis AG To Spin-Off Sandoz Business In 4Q23
11:13am, Monday, 24'th Jul 2023
Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.
